(Q46054785)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Rita De Sanctis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Laura Giordano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Armando Santoro

1 reference

ORCID Public Data File 2021

author name string

A Santoro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A Comandone

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

H Soto Parra

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

E Stroppa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

I Marcon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

F R Lutman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A Boglione

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A Bertuzzi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

9 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

1093-1098

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Targeting sarcomas: novel biological agents and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Soft tissue sarcoma trials: one size no longer fits all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Sorafenib is active on lung metastases from synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS607

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS607

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23230134%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference